Neuronal oxidative damage and denritic degeneration following activation of CD14-dependent innate immune response in vivo

Journal of Neuroinflammation

Volumn 1, Issue , 2004, Pages

  Milatovic, Dejan ^a   Zaja Milatovic, Snjezana ^a   Montine, Kathleen S ^a   Shie, Feng Shiun ^a   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CD14 ANTIGEN; GAMMA TOCOPHEROL; IBUPROFEN; LIPOPOLYSACCHARIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CELL DEGENERATION; DATA ANALYSIS; DENDRITIC CELL; IMMUNOSTIMULATION; IN VIVO STUDY; INNATE IMMUNITY; MEMBRANE DAMAGE; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATION; REVIEW;

EID: 16444372307     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-1-20     Document Type: Review

References (36)

1. Polazzi E, Contestabile A: Reciprocal interactions between microglia and neurons: from survival to neuropathology. Rev Neurosci 2002, 13:221-2242.
2. Imler JL, Hoffmann JA: Toll receptors in innate immunity. Trends Cell Biol 2001, 11:304-311.
3. Akira S: Toll-like receptor signaling. J Biol Chem 2003, 278:38105-38108.
4. Palsson-McDermott EM, O'Neill LA: Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004, 113:153-162.
5. Hata AN, Breyer RM: Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 2004, 103:147-166.
6. Johnson GB, Brunn GJ, Platt JL: Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003, 23:15-44.
7. Cook DN, Pisetsky DS, Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004, 5: 975-979.
8. Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K: The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J 2004, 18:203-205.
9. Moffatt OD, Devitt A, Bell ED, Simmons DL, Gregory CD: Macrophage recognition of ICAM-3 on apoptotic leukocytes. J Immunol 1999, 162:6800-6810.
10. Minghetti L, Levi G: Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J Neurochem 1995, 65:2690-2698.
11. Fiebich BL, Schleicher S, Spleiss O, Czygan M, Hull M: Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J Neurochem 2001, 79:950-958.
12. Roberts L J, 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998, 273:13605-136012.
13. Leuner B, Falduto J, Shors TJ: Associative memory formation increases the observation of dendritic spines in the hippocampus. J Neurosci 2003, 23:659-6665.
14. Milatovic D, Zaja-Milatovic S, Montine KS, Horner PJ, Montine TJ: Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem 2003, 87: 1518-1526.
15. Stern EL, Quan N, Proescholdt MG, Herkenham M: Spatiotemporal induction patterns of cytokine and related immune signal molecule mRNAs in response to intrastriatal injection of lipopolysaccharide. J Neuroimmunol 2000, 106:114-129.
16. Montine TJ, Milatovic D, Gupta RC, Valyi-Nagy T, Morrow JD, Breyer RM: Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 2002, 83:463-470.
17. Nadeau S, Rivest S: Endotoxemia prevents the cerebral inflammatory wave induced by intraparenchymal lipopolysaccharide injection: role of glucocorticoids and CD14. J Immunol 2002, 169:3370-3381.
18. Nadeau S, Rivest S: Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J Neurosci 2003, 23:5536-5544.
19. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts L J, 2nd, Morrow JD: Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 2002, 33:620-626.
20. Morrow JD, Roberts LJ: The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997, 36:1-21.
21. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts L J, 2nd, Morrow JD, Montine TJ: Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004, 128:117-124.
22. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann NY Acad Sci 2002, 962:318-331.
23. Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE, Longo VD: Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J Neurosci 2002, 22:3484-3492.
24. Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003, 17:13-119.
25. Beschorner R, Nguyen TD, Gozalan F, Pedal I, Mattern R, Schluesener HJ, Meyermann R, Schwab JM: CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury. Acta Neuropathol (Berl) 2002, 103:541-549.
26. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T: Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 2003, 100:8514-8519.
27. Sugimoto Y, Shigemoto R, Namba T, Negishi M, Mizuno N, Narumiya S, Ichikawa A: Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system. Neuroscience 1994, 62:919-9928.
28. Dumont I, Peri KG, Hardy P, Hou X, Martinez-Bermudez AK, Molotchnikoff S, Varma DR, Chemtob S: PGE2, via EP3 receptors, regulates brain nitric oxide synthase in the perinatal period. Am J Physiol 1998, 275:R1812-R1821.
29. Zhang J, Rivest S: Distribution, regulation and colocalization of the genes encoding EP2 and EP4 PGE2 receptors in the rat brain and neuronal responses to inflammation. Eur J Neurosci 1999, 11:2651-22668.
30. Ek M, Arias C, Sawchenko P, Ericsson-Dahlstrand A: Distribution of the EP3 prostaglandin E2 receptor subtype in the rat brain: relationship to sites of interleukin-1-induced cellular responsiveness. J Comp Neurol 2000, 428:5-20.
31. Nakamura K, Kaneko T, Yamashita Y, Hasegawa H, Katoh H, Negishi M: Immunohistochemical localization of prostaglandin EP3 receptor in the rat central nervous system. J Comp Neurol 2000, 421:543-5569.
32. McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K: Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004, 24: 257-268.
33. Reich EE, Markesbery WR, Roberts L J, 2nd, Swift LL,, Morrow JD, Montine TJ: Brain regional quantification of F-ring and D/Ering isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 2001, 158:293-2937.
34. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietzik CU, Findlay KA, Smith TE, Murphy MP, Butler T, Kang DE, Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-2216.
35. Brigelius-Flohe R, Traber MG: Vitamin E: function and metabolism. FASEB J 1999, 13:1145-1155.
36. Li Y, Liu L, Barger SW, Mrak RE, Griffin WS: Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 2001, 66:163-170.